A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Study H6D-MC-LVHQ is an observational, non-interventional, multi-center, prospective,
case-crossover study to evaluate the possible association between the use of
phosphodiesterase type 5 (PDE5) inhibitors and the risk of acute nonarteritic anterior
ischemic optic neuropathy (NAION) in males. Subjects with newly diagnosed NAION will be asked
via a structured questionnaire about their use of PDE5 inhibitors and other risk factors
prior to the onset of their vision loss.